Glaucoma News and Research

Latest Glaucoma News and Research

New study reveals another duet played by Notch and BMP signals

A small ensemble of musicians can produce an infinite number of melodies, harmonies and rhythms. So too, do a handful of workhorse signaling pathways that interact to construct multiple structures that comprise the vertebrate body.

15 May 2013

Researchers find a way the body can remove injured axons

Many medical issues affect nerves, from injuries in car accidents and side effects of chemotherapy to glaucoma and multiple sclerosis. The common theme in these scenarios is destruction of nerve axons, the long wires that transmit signals to other parts of the body, allowing movement, sight and sense of touch, among other vital functions.

10 May 2013

Study: Gene mutations are associated with severe form of nearsightedness

People have long taken for granted that glasses and contact lenses improve vision for nearsightedness, but the genetic factors behind the common condition have remained blurry. Now researchers at Duke Medicine are closer to clearing this up.

3 May 2013

Exposure to daylight helps protect children from myopia

Two new studies add to the growing evidence that spending time outdoors may help prevent or minimize nearsightedness in children. A study conducted in Taiwan, which is the first to use an educational policy as a public vision health intervention, finds that when children are required to spend recess time outdoors, their risk of nearsightedness is reduced.

2 May 2013

Fixed-dose combination of drugs effectively lowers IOP

A fixed-dose combination of brinzolamide and brimonidine is more effective than either drug given alone for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, results of a phase III trial indicate.

25 Apr 2013

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dry age-related macular degeneration has been initiated.

25 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Amakem backs new Chair of Ophthalmology Translational Research at KU Leuven

Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has sponsored a new Chair of Ophthalmology Translational Research at the Catholic University Leuven (KU Leuven), Belgium.

8 Apr 2013

Professor of neurology outlines case studies of hallucinations of musical notation

Professor of neurology, physician, and author Oliver Sacks M.D. has outlined case studies of hallucinations of musical notation, and commented on the neural basis of such hallucinations, in a new paper for the neurology journal Brain.

5 Apr 2013

Lund University researchers examine why people suffer vision loss in eye diseases

Using new technology and new approaches, researchers at Lund University in Sweden hope to be able to explain why people suffer vision loss in eye diseases such as retinal detachment and glaucoma.

4 Apr 2013

pSivida announces resubmission of ILUVIEN NDA to FDA for chronic diabetic macular edema

pSivida Corp., a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported the submission of its response to the second Complete Response Letter from the U.S. Food and Drug Administration with respect to ILUVIEN for chronic diabetic macular edema.

2 Apr 2013

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

VIVUS, Inc. announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients.

25 Mar 2013

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

R-Tech Ueno is pleased to announce the start of the patient enrollment of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in our company for the treatment of retinitis pigmentosa.

18 Mar 2013

Reduced visual sensitivity seen with use of multifocal intraocular lenses

Recent study findings indicate that eyes with multifocal intraocular lenses implanted during cataract surgery may develop reduced visual sensitivity.

8 Mar 2013

Oraya Therapy safe and effective for patients with wet AMD

Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.

1 Mar 2013

Vision CRC develops retinal camera for detection of blinding eye disease and general health disorders

The most advanced technology for use in real-time detection and assessment of common blinding eye disease and general health disorders will soon be available to the world with stimulus funding provided for development by the Australian Government's CRC Program.

27 Feb 2013

Sucampo launches RESCULA Eye Drops in the U.S.

Sucampo Pharmaceuticals, Inc. announced that RESCULA Eye Drops had been launched in the U.S. market.

21 Feb 2013

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo Pharmaceuticals, Inc. today announced that RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% is now available by prescription across the United States. The U.S. Food and Drug Administration (FDA) approved a sNDA for RESCULA for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension on December 7, 2012.

19 Feb 2013

Meridian Health, Bayshore Community Hospital announce $5 million charitable contribution

Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."

16 Feb 2013

Glaucoma News and Research

Latest Glaucoma News and Research

New study reveals another duet played by Notch and BMP signals

Researchers find a way the body can remove injured axons

Study: Gene mutations are associated with severe form of nearsightedness

Exposure to daylight helps protect children from myopia

Fixed-dose combination of drugs effectively lowers IOP

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

BD receives FDA approval for second prefilled injectable drug

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Amakem backs new Chair of Ophthalmology Translational Research at KU Leuven

Professor of neurology outlines case studies of hallucinations of musical notation

Lund University researchers examine why people suffer vision loss in eye diseases

pSivida announces resubmission of ILUVIEN NDA to FDA for chronic diabetic macular edema

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

R-Tech Ueno enrolls retinitis pigmentosa patients in Phase 3 clinical study of UF-021 ophthalmic solution

Reduced visual sensitivity seen with use of multifocal intraocular lenses

Oraya Therapy safe and effective for patients with wet AMD

Vision CRC develops retinal camera for detection of blinding eye disease and general health disorders

Sucampo launches RESCULA Eye Drops in the U.S.

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Meridian Health, Bayshore Community Hospital announce $5 million charitable contribution

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Glaucoma News and Research

Latest Glaucoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in